ClinicalTrials.gg
CompletedNCT05653271Updated Jun 30, 2026

ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies

A Phase 1 interventional study of Cyclophosphamide and Fludarabine in B-cell Lymphoma, Non Hodgkin Lymphoma and DLBCL, sponsored by Acepodia Biotech, Inc.. Completed at 13 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-30.

Primary conditionBurkitt LymphomaRegistry: Lymphoma, B-CellReclassifiedWhy we changed it
Registry
Lymphoma, B-Cell — the first condition term the registry derived for this study.
ClinicalTrials.gg
Burkitt Lymphoma
Why
  1. The study's listed conditions name Burkitt Lymphoma, a narrower term within Lymphoma, B-Cell.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Acepodia Biotech, Inc. · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

ACE1831 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment of CD20-expressing B-cell malignancies.

The ACE1831-001 study is an open-label, Phase I, first-in-human (FIH) study that aims to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, and efficacy of ACE1831 in patients with CD20-expressing Non-Hodgkin lymphoma.

02

Conditions studied

  • B-cell Lymphoma
  • Non Hodgkin Lymphoma
  • DLBCL
  • Primary Mediastinal Large B Cell Lymphoma
  • Marginal Zone Lymphoma
  • Follicular Lymphoma
  • Burkitt Lymphoma
  • High-grade B-cell Lymphoma
03

In context

Burkitt Lymphoma Reclassified

978 studies on the registry are indexed under Burkitt Lymphoma; 160 are open to participants now.

This study's enrollment of 16 is below the median of 36 across 767 interventional studies indexed under Burkitt Lymphoma.

Browse Burkitt Lymphoma studies →

Lead sponsor

Acepodia Biotech, Inc. is the lead sponsor of 5 studies on the registry; 2 are open to participants now.

Compared within Burkitt Lymphoma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lymphoma, B-Cell. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • CD20-positive B-cell NHL that is persistent or progressive after having received at least 2 prior systemic therapies per NCCN guidelines
  • At least 1 according to the revised International Working Group (IWG) Response Criteria for Malignant Lymphoma
  • (ECOG) Performance Status 0-1 or subjects with ECOG scores of 2 with a serum albumin of >3.5
  • Adequate hematologic and renal, hepatic, and cardiac function
  • Oxygen saturation via pulse oxygenation ≥ 92% at rest on room air

Key Exclusion Criteria:

  • Prior treatment with a genetically modified cell therapy product targeting CD20
  • stem cell transplant within 6 weeks of or history of allogeneic stem cell transplantation
  • History of central nervous system (CNS) lymphoma or primary CNS lymphoma
  • History or presence of CNS disorder (e.g. epilepsy)
  • Clinically significant active infection
  • Currently active, clinically significant cardiovascular disease
  • (HIV) infection (however, subjects on anti-retroviral therapy for at least 4 weeks and with HIV viral loads of \<400 copies/mL are eligible), active infection, or infection
  • History of other with the exception of certain treated malignancies with no evidence of disease
  • Primary immunodeficiency disorder
  • Pregnant or lactating female
  • Any medical, psychological, familial, or sociological conditions that, in the opinion of the Investigator or Sponsor Medical Monitor, would impair the ability of the subject to receive study treatment, comply with study requirements, or understanding of the informed consent
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Treatment Group A (ACE1831)

    ACE1831 dose escalation, monotherapy. Lymphodepleting regimen followed by escalating doses of ACE1831.

    Drug: Cyclophosphamide · Drug: Fludarabine · Drug: ACE1831

  • Experimental
    Treatment Group B (ACE1831 and obinutuzumab)

    ACE1831 dose escalation, in combination with obinutuzumab. Lymphodepleting regimen followed by escalating doses of ACE1831, given in combination with obinutuzumab.

    Drug: Cyclophosphamide · Drug: Fludarabine · Drug: ACE1831 · Drug: Obinutuzumab

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events (AEs), Dose Limiting Toxicities (DLTs), adverse events of special interest (AESIs), and serious adverse events (SAEs)

    Time frame: 2 years

  2. Change from baseline in ECOG status

    Time frame: 1 year

  3. Change from baseline in physical examination results

    Number of subject with change from baseline clinically significant physical examination findings by dose level (descriptive)

    Time frame: 1 year

  4. Change from baseline clinical laboratory tests results

    Number of subjects with change from baseline clinically significant lab findings by dose level (descriptive)

    Time frame: 1 year

  5. Change from baseline in urinalysis results

    Number of subjects with change from baseline clinically significant urinalysis findings by dose level (descriptive)

    Time frame: 1 year

  6. Change from baseline in vital signs results

    Number of subjects with change from baseline clinical significant vital signs findings by dose level (descriptive)

    Time frame: 1 year

  7. Change from baseline in electrocardiogram (ECG) results

    Number of subjects with change from baseline clinically significant ECG findings by dose level (descriptive)

    Time frame: 1 month

  8. Maximum Tolerated Dose (MTD)

    Time frame: 1 month

Secondary outcomes

  1. Persistence of ACE1831 after administration

    Half-life of ACE1831

    Time frame: 1 month

  2. Measure of anti-ACE1831 antibodies after administration

    Titration of anti-ACE1831 antibodies after administration

    Time frame: 1 month

  3. Objective Response Rate (ORR)

    Objective response of each patient's underlying lymphoma, duration of response, and progression-free survival all based on the revised IWG Response Criteria for Malignant Lymphoma

    Time frame: 2 years

Other outcomes

  1. Pharmacodynamics of ACE1831

    Serum levels of interferon-γ, TNF-α, IL-2, IL-6, IL-8 and IL-10, as well as other potential biomarkers

    Time frame: 2 years

07

Study locations

13 sites
  • AdventHealth Orlando
    Orlando, Florida 32804, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • Indiana University Simon Comprehensive Cancer Center
    Indianapolis, Indiana 46202, United States
  • Norton Cancer Institute
    Louisville, Kentucky 40207, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Queen Mary Hospital
    Hong Kong, Hong Kong, Hong Kong
  • Kaohsiung Chang-Gung Memorial Hospital
    Kaohsiung City, Kaohsiung, Taiwan
  • National Cheng Kung University Hospital
    Tainan, Tainan, Taiwan
  • National Taiwan University Hospital
    Taipei, Taipei, Taiwan
  • Ministry of Health and Welfare Shuang-Ho Hospital
    New Taipei City, Taiwan, Taiwan
  • Taichung Veterans General Hospital
    Taichung, Taiwan, Taiwan
  • Tamsui MacKay Memorial Hospital
    New Taipei City, Taiwan
  • Linkou Chang-Gung Memorial Hospital
    Taoyuan City, Taiwan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2023 to primary completion in Mar 2026, 38 months.

Of 110 phase 1 interventional studies under Burkitt Lymphoma, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 90. This study's 38 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2022
First posted
Dec 16, 2022
StartActual
Jan 21, 2023
Primary completionActual
Mar 31, 2026
CompletionActual
Mar 31, 2026
Last update
Jun 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05653271
Lead sponsor
Acepodia Biotech, Inc.
Responsible party
Sponsor
First posted
Dec 16, 2022
Start date
Jan 21, 2023
Primary completion
Mar 31, 2026
Completion
Mar 31, 2026
Last update
Jun 30, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Allogeneic Rituximab Conjugated Gamma Delta T-cells ACE1831

Start the discussion